Nicolas Meillan1, Dewi Vernerey2, Jérémie H Lefèvre3, Gilles Manceau4, Magali Svrcek5, Jeremy Augustin6, Jean-François Fléjou5, Olivier Lascols7, Jean-Marc Simon8, Romain Cohen9, Philippe Maingon10, Jean-Baptiste Bachet11, Florence Huguet12. 1. Department of Radiation Oncology, Tenon Hospital, Hôpitaux Universitaires Paris Est, APHP, Paris, France. 2. Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France. 3. Department of Digestive Surgery, Saint-Antoine Hospital, APHP, Paris, France; Sorbonne Université, Paris, France. 4. Sorbonne Université, Paris, France; Department of Digestive and Hepato-Pancreato-Biliary Surgery, Pitié Salpêtrière Hospital, APHP, Paris, France. 5. Sorbonne Université, Paris, France; Department of Pathology, Saint-Antoine Hospital, APHP, Paris, France. 6. Department of Pathology, Pitié Salpêtrière Hospital, APHP, Paris, France. 7. Department of Biology and Molecular Genetics, Saint-Antoine Hospital, APHP, Paris, France. 8. Department of Radiation Oncology, Pitié Salpêtrière Hospital, APHP, Paris, France. 9. Sorbonne Université, Paris, France; Department of Medical Oncology, Saint-Antoine Hospital, APHP, Paris, France. 10. Sorbonne Université, Paris, France; Department of Radiation Oncology, Pitié Salpêtrière Hospital, APHP, Paris, France. 11. Sorbonne Université, Paris, France; Department of Hepato-Gastroenterology, Pitié Salpêtrière Hospital, APHP, Paris, France. 12. Department of Radiation Oncology, Tenon Hospital, Hôpitaux Universitaires Paris Est, APHP, Paris, France; Sorbonne Université, Paris, France. Electronic address: florence.huguet@aphp.fr.
Abstract
PURPOSE: Defective mismatch repair system (dMMR) has been shown to have a favorable impact on outcome in patients with colorectal cancer treated with surgery or immunotherapy, with adjuvant chemotherapy being discouraged unless there is nodal involvement. Its impact on radiosensitivity is unknown in patients with colorectal cancer. METHODS AND MATERIALS: Patients treated for locally advanced rectal cancer between 2000 and 2016 were studied. Reported points included age, sex, clinical and radiologic tumor stages at diagnosis, modalities of neoadjuvant treatment, posttreatment pathologic staging, tumor regression score, and local, distant relapse-free, and overall survival. An inverse probability of treatment weighting propensity score analysis was performed to evaluate the association of mismatch repair proficiency with surgical and clinical outcomes. RESULTS: Among the 296 patients included, 23 (7.8%) had dMMR. Median follow-up was 43.0 months (interquartile range, 27.9-66.7). Patients with dMMR were significantly younger than the others. After inverse probability of treatment weighting propensity score matching, dMMR patients had higher pathologic downstaging rate (P < .0001), higher tumor regression grade (P = .024), and a longer recurrence-free survival (P < .0001). CONCLUSIONS: dMRR was associated with significant tumor downstaging after neoadjuvant chemoradiation and with increased recurrence-free survival. dMMR patients may have more radiosensitive tumors.
PURPOSE: Defective mismatch repair system (dMMR) has been shown to have a favorable impact on outcome in patients with colorectal cancer treated with surgery or immunotherapy, with adjuvant chemotherapy being discouraged unless there is nodal involvement. Its impact on radiosensitivity is unknown in patients with colorectal cancer. METHODS AND MATERIALS: Patients treated for locally advanced rectal cancer between 2000 and 2016 were studied. Reported points included age, sex, clinical and radiologic tumor stages at diagnosis, modalities of neoadjuvant treatment, posttreatment pathologic staging, tumor regression score, and local, distant relapse-free, and overall survival. An inverse probability of treatment weighting propensity score analysis was performed to evaluate the association of mismatch repair proficiency with surgical and clinical outcomes. RESULTS: Among the 296 patients included, 23 (7.8%) had dMMR. Median follow-up was 43.0 months (interquartile range, 27.9-66.7). Patients with dMMR were significantly younger than the others. After inverse probability of treatment weighting propensity score matching, dMMRpatients had higher pathologic downstaging rate (P < .0001), higher tumor regression grade (P = .024), and a longer recurrence-free survival (P < .0001). CONCLUSIONS:dMRR was associated with significant tumor downstaging after neoadjuvant chemoradiation and with increased recurrence-free survival. dMMRpatients may have more radiosensitive tumors.
Authors: Mingzhu Sun; Jayne Moquet; Michele Ellender; Simon Bouffler; Christophe Badie; Rachel Baldwin-Cleland; Kevin Monahan; Andrew Latchford; David Lloyd; Susan Clark; Nicola A Anyamene; Elizabeth Ainsbury; David Burling Journal: Fam Cancer Date: 2022-06-20 Impact factor: 2.375
Authors: Catarina Frias-Gomes; Ana Carla Sousa; Inês Rolim; Ana Raquel Henriques; Francisco Branco; André Janeiro; Sara Malveiro; Ana Rita Dário; Maria Helena Oliveira; Paula Borralho; José Alberto Teixeira; Ana Faria; Rui Maio; Isabel Fonseca; Marília Cravo Journal: GE Port J Gastroenterol Date: 2021-05-27
Authors: Marloes Swets; Cristina Graham Martinez; Shannon van Vliet; Arjan van Tilburg; Hans Gelderblom; Corrie A M Marijnen; Cornelis J H van de Velde; Iris D Nagtegaal Journal: Histopathology Date: 2022-07-14 Impact factor: 7.778